The Predictive Power of Serum Vitamin D for Poor Outcomes in COVID-19 Patients

Hoda Derakhshanian  
Alborz University of Medical Sciences,

Hadith Rastad  
Alborz University of Medical Sciences,

Sanjoy Ghosh  
University of British Columbia

Marjan Zeinali  
Iran University of Medical Sciences

Tara Khoeini  
Iran University of Medical Sciences

Mohsen Farrokhpour  
Iran University of Medical Sciences

Mostafa Qorbani  
Alborz University of Medical Sciences,

Mona Ramezani Ghamsari  
Alborz University of Medical Sciences,

Hossein Hasani  
Tehran University of Medical Sciences

Zahra Mirzaasgari (✉️ mirzaasgari@gmail.com)  
Iran University of Medical Sciences

Research Article

Keywords: Coronavirus infections, COVID-19, Vitamin D

DOI: https://doi.org/10.21203/rs.3.rs-140417/v1

License: ☝️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background: Considering the high prevalence of vitamin D deficiency worldwide and its relationship with immune response to viral infections, this study attempted to identify the predictive power of serum vitamin D for poor outcomes among the COVID-19 patients.

Methods: This retrospective cohort study included all patients with confirmed COVID-19 hospitalized between 20 February 2020 and 20 April 2020 at a designated COVID-19 hospital, located in Tehran province, Iran. General characteristics, medical history, and clinical symptoms were recorded by trained physicians. Blood parameters including complete blood count, creatinine, lactate dehydrogenase, creatine phosphokinase, erythrocyte sedimentation rate, C-reactive protein, and vitamin D were tested.

Results: This study included 290 hospitalized patients with COVID-19 (the mean age (SD): 61.6 (16.9), 56.6% males), of whom 142 had vitamin D concentrations less than 20 ng/ml, defined as vitamin D deficiency. COVID-19 patients with vitamin D deficiency were more likely to die (Crude OR (95% CI): 2.30 (1.25-4.26)), require ICU care (2.06 (1.22-3.46)) and invasive mechanical ventilation (2.03 (1.04-3.93)) based on univariate logistic regression results. However, after adjusting for potentials confounders such as gender and age, the association between vitamin D and need to invasive mechanical ventilation lost its significance.

Conclusion: Vitamin D deficiency can be considered as a predictor of poor outcomes and mortality in COVID-19 patients. Therefore, checking serum 25 (OH) D on admission and taking vitamin D supplements according to the prophylactic or treatment protocols is recommended for all COVID-19 patients.

Introduction

Since the world has faced the pandemic of COVID-19, several studies have been established to elucidate the pathophysiology and treatment of this disease. The epidemiological surveys show that the disease is highly contagious. However, its severity widely ranges from no symptoms to death.(1, 2) So, in this situation, understanding the risk factors affecting the patient's response to the novel coronavirus is of great importance. Beside age, gender, underlying illnesses and general nutritional status, vitamin D has been under the spotlight in scientific debates.(3) Vitamin D took attention because it is known as an immunomodulator over the last decades.(4) Vitamin D in the form of calcitriol, can bind to its nuclear receptor (VDR) and contribute to modifying the cells transcriptional output. Several reviews suggested that, vitamin D plays a role in reducing the risk of viral infections by affecting cellular natural and adaptive immunity.(5) The antiviral properties of this vitamin are also due to its ability in suppressing the expression of pro-inflammatory factors, increasing the expression of anti-inflammatory cytokines, promoting the induction of the T regulatory cells, and upregulation of the anti-microbial/anti-viral peptides such as cathelicidin and defensins.(6, 7) In addition, vitamin D interacts with the renin-angiotensin system (RAS), which is known to be involved in COVID-19 infection.(8) Considering the high
prevalence of vitamin D deficiency worldwide, the present study attempted to identify the predictive power of serum vitamin D for poor outcomes among the COVID-19 patients.

Materials And Methods

Study design and participants

Our retrospective cohort study included all patients with confirmed COVID-19 hospitalized between 20 February 2020 and 20 April 2020 at a designated COVID-19 hospital, located in the province of Tehran, Iran. We excluded patients from the study if they were still hospitalized or their vitamin D level was not measured.

Data collection

Two trained physicians extracted data on the following variables from the medical records of discharged patients: age, gender, medical history, clinical signs, symptoms, O2 saturation, requiring invasive mechanical ventilation on admission, the first laboratory findings in the hospital, discharged status (dead or alive), also real-time polymerase chain reaction (RT-PCR) test and chest computed tomography (CT) scan findings.

This research adhered to the Declaration of Helsinki guidelines. Research and Ethics Committees of Alborz University of Medical Sciences (ABZUMS) and Iran University of Medical Sciences (IUMS) reviewed and approved the study protocol and waived the requirements for informed consent. To protect confidentiality and anonymity of the patients, a unique identification number was assigned to each included patient.

COVID-19 diagnosis

COVID-19 diagnosis was confirmed by one of the following criteria: 1) a positive RT–PCR result or 2) a positive pulmonary abnormality on chest CT based on the radiological criteria of COVID-9 infection.\(^\text{9, 10}\)

Laboratory testing

In two aforementioned hospitals, the oropharyngeal swab specimens of patients were collected on admission and examined in predetermined laboratories to detect SARS-CoV-2 viral nucleic acid using RT-PCR assay. Blood parameters listed below were extracted from the first blood tests results for each patient: complete blood count (CBC) including white blood cells (WBC) count and type, hemoglobin (Hb), creatinine, lactate dehydrogenase (LDH), creatine phosphokinase (CPK), erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), aspartate and alanine transaminases (AST, ALT), Prothrombin time (PT), partial thromboplastin time (PTT), and Vitamin D.

Comorbidity
On admission, patients were asked if they had a medical history of the comorbidities including: diabetes mellitus (DM), hypertension (HTN), cardiovascular disease (CVD), cancer, chronic renal failure (CRF) (dialysis or non-dialysis), chronic liver diseases, psychological disorder, chronic pulmonary disease, asthma, thyroid dysfunction, immunodeficiency, autoimmune disease, hematologic disease, and neurological disorder.

**COVID-19 Outcomes**

Based on the discharge status, patients were classified as cured (survivors) or dead (non-survivors). Need for ICU care and need for invasive mechanical ventilation were also considered as criteria for severity of disease. In our hospitals, COVID-19 patients who met all following criteria will be discharged: lack of fever for at least 72 h, alleviation of respiratory symptoms, and improvement in pulmonary abnormalities on chest CT scan.

**Statistical analysis**

We summarized the general and clinical characteristics of the cohort using appropriate descriptive statistics, mean (standard deviation (SD)) or median (interquartile range (IQR)), for continuous variables and frequency (%) for categorical variables. Vitamin D deficiency was defined as the vitamin D concentrations less than 20 ng/ml. Then patients fall into two groups with or without vitamin D deficiency. We compared characteristics of patients with and without vitamin D deficiency using two-tailed t-tests, Mann–Whitney U tests or Chi-square tests.

The receiver operating curve (ROC) analysis was performed to compare the predictive abilities of vitamin D concentration and other blood parameters for predicting the poor outcomes of COVID-19; area under the curve (AUC) and its 95% confidence interval (CIs) are reported for each assessed parameter. Univariable and Multivariable logistic regression models were used to assess the association of vitamin D deficiency with each poor outcomes of COVID-19 including death, need to ICU care, and receiving invasive mechanical intubation. Of factors associated with vitamin D deficiency, those with a \( P \)-value < 0.2 on univariate analysis were entered into multivariable logistic as a potential confounder. Results are presented as crude and adjusted odds ratio (OR) and 95% CI. We also performed a log-rank test to determine if there were differences in the survival distribution between males and females and two age groups \( \geq 65 \) years and < 65 years. A \( P \)-value of less than 0.05 was considered as statistically significant. All statistical analyses were performed using STATA version11 (Stata Corp LP, College Station, TX, USA).

**Results**

For the present analyses, 290 COVID-19 patients who were hospitalized during the study period were included, of whom 142 had vitamin D deficiency. Table 1 presents general characteristics and disease-related symptoms in the study population on admission, overall and by vitamin D deficiency status. The mean age (SD) of patients was 61.6 (16.9) and 56.6% of them (\( n = 164 \)) were male.
Table 1
General characteristics and disease-related symptoms in the study population, overall and by vitamin D status

| Variables                        | Total N = 290 | Without vitamin D deficiency N = 148 | With vitamin D deficiency N = 142 | \(P\)-value |
|----------------------------------|---------------|--------------------------------------|----------------------------------|-------------|
| Demographic                      |               |                                      |                                  |             |
| Age (year), mean (SD)            | 61.6 (16.9)   | 60.3 (16.1)                          | 63.0 (17.6)                      | 0.183       |
| Age ≥ 65 year, % (N)             | 42.4 (123)    | 39.2 (58)                            | 45.8 (65)                        | 0.257       |
| Gender male, % (N)               | 56.6 (164)    | 50.0 (74)                            | 63.4 (90)                        | 0.022       |
| COVID-19-related symptoms, % (N)|               |                                      |                                  |             |
| Cough                            | 48.4 (140)    | 53.4 (79)                            | 42.9 (61)                        | 0.076       |
| Fever                            | 40.3 (112)    | 39.6 (57)                            | 41.0 (55)                        | 0.804       |
| Tiredness                        | 41.0 (103)    | 38.8 (52)                            | 43.6 (51)                        | 0.442       |
| \(P_{O_2} < 93\%\)              | 55.0 (153)    | 50.0 (72)                            | 60.4 (81)                        | 0.080       |
| Comorbidities, % (N)             |               |                                      |                                  |             |
| DM                               | 31.5 (87)     | 30.3 (44)                            | 32.8 (43)                        | 0.658       |
| HTN                              | 34.2 (95)     | 36.3 (53)                            | 31.8 (42)                        | 0.431       |
| CVD                              | 21.6 (59)     | 21.4 (31)                            | 21.9 (28)                        | 0.921       |
| Other comorbidities*             | 30.5 (84)     | 30.3 (44)                            | 30.8 (40)                        | 0.939       |
| Any comorbidity                  | 64.7 (178)    | 63.9 (92)                            | 65.6 (86)                        | 0.760       |

* Including: cancer, rheumatism, immunodeficiency, or chronic respiratory, hepatic, and blood diseases. DM: Diabetes mellitus. CVD: Cardiovascular disease. HTN: Hypertension.

The most common complaints on admission, in order by frequency, were cough (48.4%), tiredness (41.0 %), and fever (40.3 %). Besides, O₂ saturation less than “93%” were observed in 55.0 % (n = 153) of patients. About 65 % (178) of patients reported at least, one comorbidity the most common of which was hypertension (34.2%), followed by diabetes mellitus (31.5%) and cardiovascular disease (21.6%).
Out of 290 patients, 82 (28.3%) received ICU care, 43 (14.8%) required invasive mechanical ventilation, and 55 (19.0%) died during hospitalization.

Compared to patients without vitamin D deficiency, the proportion of males was significantly higher in those with vitamin D deficiency (63.4% vs. 50.0%, \( P \)-value = 0.022); other assessed characteristics, including prevalence of underlying diseases, were similar between the two groups (all \( P \)-values > 0.05).

Regarding the assessed poor outcomes of COVID-19, higher percentage of patients with vitamin D deficiency died (27.7% vs. 14.3%; \( P \)-value = 0.005), received ICU care (37.8% vs. 23.4%; \( P \)-value = 0.006) and needed invasive mechanical ventilation (19.9% vs. 11.0%, \( P \)-value = 0.036).

Table 2 shows the laboratory findings of patents at the first day of admission, overall and by vitamin D deficiency status. There was no statistically significant difference between the two groups regarding the assessed laboratory parameters.
Table 2
Laboratory findings of the study population on admission, overall and by vitamin D status status

| Characteristics                      | Total     | Without vitamin D deficiency | With vitamin D deficiency | P-value |
|--------------------------------------|-----------|------------------------------|---------------------------|---------|
| WBC count (×10^9/L), Median (IQR)    | 6.1 (4.6–8.4) | 5.7 (4.3–8.2) | 6.7 (4.9–8.9) | 0.143   |
| Lymphocyte count (× 10^9/L), Median (IQR) | 1.9 (1.3–2.6) | 2.0 (1.4–2.6) | 1.8 (1.2–2.5) | 0.594   |
| AST (U/L), Median (IQR)              | 38.0 (29.0–55.7) | 37.0 (28.0–53.5) | 38.0 (29.0–63.0) | 0.996   |
| ALT (U/L), Median (IQR)              | 28.0 (19.0–44.7) | 30.0 (19.0–45.0) | 28.0 (19.0–44.0) | 0.551   |
| Creatinine (mg/dl), Median (IQR)     | 1.10 (0.9–1.3) | 1.00 (0.9–1.3) | 1.10 (0.9–1.3) | 0.584   |
| LDH (U/L), Median (IQR)              | 590.5 (469.5–824.7) | 563.5 (481.2–820.3) | 614.0 (454.0–830.5) | 0.345   |
| Hb (g/Dl), Median (IQR)              | 13.1 (11.5–14.4) | 13.2 (11.8–14.5) | 12.8 (11.0–14.3) | 0.209   |
| ESR (mm/h), Median (IQR)             | 41.0 (26.5–58.7) | 40.0 (25.0–55.0) | 42.5 (30.0–63.3) | 0.144   |
| CRP > 3+, % (N)                      | 20.0 % (50) | 18.6% (24) | 21.5% (26) | 0.569   |
| CPK (U/L), Median (IQR)              | 163 (75–286) | 170.5 (75.0–287.0) | 145.0 (70.0–274.0) | 0.823   |
| PT (S), Median (IQR)                 | 13.5 (13.0–14.00) | 13.5 (13.0-14.45) | 13.5 (13.5–15.40) | 0.233   |

WBC: White blood cells, IQR: Inter quartile range, ALT: Alanine transaminases, AST: Aspartate transaminases, CRP: C-reactive protein, CPK: Creatine phosphokinase, ESR: Erythrocyte sedimentation rate, Hb: Hemoglobin, LDH: Lactate dehydrogenase, PT: Prothrombin time

Table 3 presents associations between vitamin D deficiencies with the poor outcomes of COVID-19 separately, including death, need to ICU care, and invasive mechanical ventilation based on the results of logistic regression models. Results from univariate logistic regression analysis showed that COVID-19 patients with vitamin D deficiency were more likely to die (Crude OR (95% CI): 2.30 (1.25–4.26)), require ICU care (2.06 (1.22–3.46)) and invasive mechanical ventilation (2.03 (1.04–3.93)) than those without vitamin D deficiency; however, in the multivariate logistic regression analysis, after considering potential confounders such as age and gender, the association of vitamin D deficiency with being intubated did not reach to the statistical significance (adjusted OR (95% CI): 1.84 (0.93–3.62); P-value = 0.084).
## Table 3
AUC of Laboratory test for predicting death and requiring ICU care in patients with COVID-19

| Test                        | Death     |              |              | Need to ICU care |              |              | Need to invasive mechanical ventilation |              |
|-----------------------------|-----------|--------------|--------------|------------------|--------------|--------------|------------------------------------------|--------------|
|                             | AUC (95% CI) | P-value     | AUC (95% CI) | P-value          | AUC (95% CI) | P-value | AUC (95% CI) | P-value |
| WBC count, × 10⁹/L          | 0.59 (0.49–0.69) | 0.044       | 0.61 (0.53–0.69) | 0.004            | 0.57 (0.46–0.68) | 0.121 |
| Lymphocyte count, × 10⁹/L   | 0.71 (0.62–0.79) | < 0.001     | 0.61 (0.53–0.68) | 0.006            | 0.70 (0.60–0.76) | < 0.001 |
| Hb, g/dL                    | 0.63 (0.54–0.73) | 0.003       | 0.59 (0.51–0.67) | 0.016            | 0.60 (0.50–0.70) | 0.038 |
| Creatinine, mg/dl           | 0.72 (0.64–0.81) | < 0.001     | 0.66 (0.58–0.73) | < 0.001          | 0.70 (0.61–0.80) | < 0.001 |
| AST, U/L                    | 0.59 (0.50–0.68) | 0.040       | 0.56 (0.49–0.64) | 0.093            | 0.56 (0.46–0.66) | 0.213 |
| ALT, U/L                    | 0.50 (0.41–0.59) | 0.991       | 0.46 (0.39–0.54) | 0.344            | 0.44 (0.35–0.53) | 0.229 |
| LDH, U/L                    | 0.64 (0.54–0.74) | 0.006       | 0.59 (0.50–0.68) | 0.033            | 0.60 (0.46–0.72) | 0.073 |
| CPK, U/L                    | 0.68 (0.58–0.78) | 0.001       | 0.57 (0.48–0.66) | 0.133            | 0.69 (0.58–0.79) | 0.001 |
| ESR, mm/h                   | 0.46 (0.37–0.56) | 0.420       | 0.48 (0.40–0.56) | 0.548            | 0.50 (0.40–0.60) | 0.968 |
| PT, S                       | 0.72 (0.64–0.80) | < 0.001     | 0.68 (0.61–0.75) | < 0.001          | 0.68 (0.58–0.77) | < 0.001 |
| Vitamin D, ng/mL            | 0.63 (0.54–0.72) | 0.003       | 0.57 (0.50–0.65) | 0.051            | 0.61 (0.52–0.71) | 0.017 |

ALT = Alanine transaminases. AST = Aspartate transaminases. CRP = C-reactive protein. CPK = Creatine phosphokinase. ESR = Erythrocyte sedimentation rate Hb = Hemoglobin. LDH: Lactate dehydrogenase. PT = Prothrombin time. WBC = White blood cell.

Table 4 shows AUC and its 95% confidence interval (CI) of laboratory parameters including vitamin D concentrations for predicting poor outcomes of COVID-19. Vitamin D concentrations was among the parameters with the significant diagnostic accuracy for the early detection of COVID-19 death (AUC (95% CI: 62.9 (54.1–71.7)) and need to ICU care (61.3 (51.7–71.0)); its diagnostic accuracy in detecting need to invasive mechanical ventilation was marginally non-significant. However, vitamin D concentration had significantly lower predictive ability compared to lymphocyte count, creatinine, and CPK in the predicting COVID-19 death and requiring ICU care (both $P$-values < 0.001, Fig. 1).
Table 4
Prognostic impact of vitamin D deficiency for need to ICU, need to invasive mechanical ventilation and death following COVID-19: Logistic Regression Analysis

| Variable                  | Death Crude OR (95% CI) | Death Adjusted* OR (95% CI) | Need to ICU Crude OR (95% CI) | Need to ICU Adjusted* OR (95% CI) | Need to invasive mechanical ventilation Crude OR (95% CI) | Need to invasive mechanical ventilation Adjusted* OR (95% CI) |
|---------------------------|-------------------------|-----------------------------|-----------------------------|---------------------------------|--------------------------------------------------------|----------------------------------------------------------|
| Vitamin D deficiency      | 2.30 (1.25–4.26) †      | 2.0 (1.03–3.83) †           | 2.06 (1.22–3.46) †          | 1.83 (1.07–3.14) †             | 2.03 (1.04–3.93) †                                      | 1.84 (0.93–3.62) †                                       |

OR: Odds Ratio, CI: Confidence Interval, * Adjusted for age and sex, † P-value < 0.05

Discussion

According to our study, COVID-19 patients with vitamin D deficiency (a serum level of less than 20 ng/dl) were about twice as much at risk for ICU hospitalization and death, even after adjusting the statistical model for age and gender.

In a recent study, linking the data from UK Biobank to COVID-19 test results revealed an association between vitamin D and COVID-19 infection which was not significant after adjustment for confounders. Among the 348,598 participants, 449 tested positive for COVID-19. The median serum 25(OH)D concentration was lower in COVID-19 positive patients. However, after performing univariable logistic regression analysis adjusted for confounding factors, the authors found no strong evidence to support a potential protective role of vitamin D against COVID-19 infection.(11)

Another retrospective multicentral study of 212 cases with laboratory-confirmed infection of SARS-CoV-2 showed that serum 25(OH)D level was lowest in critical cases, and a decrease in serum 25(OH)D level could worsen clinical outcomes of the patients.(12)

Meltzer et al. studied the documents of 4,314 patients tested for COVID-19. Of those, 499 had had a vitamin D result during the last year, and 178 (36%) cases were diagnosed as vitamin D deficient. The multivariable analysis suggested that persons with vitamin D deficiency were at a substantially higher risk of testing positive for COVID-19.(13)

Several possible mechanisms can link vitamin D to COVID-19. Firstly, it is now clear that vitamin D plays important roles in the modulation of the immune system and its low level is associated with both increased autoimmune and infectious diseases. Calcitriol, the active form of vitamin D, has its own nuclear receptor (VDR) trough which can alter gene expression. To our knowledge, immunologic cells are capable of synthesizing the active calcitriol, and the VDRs have been found in these cells as well. Therefore, vitamin D can even act in a paracrine or autocrine manner to affect immunity.(14)
Vitamin D improves physical protection against pathogens by maintaining junction integrity.\(^{(15)}\) It also enhances cellular innate immunity partly through the induction of antimicrobial peptides (such as cathelicidin and defensins) as well as reducing the cytokine storm which has been widely observed in COVID-19 patients.\(^{(16)}\) Vitamin D is a modulator of adaptive immunity via suppressing responses mediated by the T helper cells type 1 (Th1), promoting cytokine production by the T helper cells type 2 (Th2), and improving induction of the T regulatory cells, thereby inhibiting inflammatory processes.\(^{(17)}\) It therefore comes as no surprise why many documents depict an association between lower vitamin D levels and a higher rate of upper respiratory tract infection, influenza, bacterial vaginosis, HIV and other viral or microbial infections.\(^{(18–22)}\)

A recent study claimed that subtropical and mid-latitude countries are most affected by COVID-19. This finding, if correct, might be partly explained by the higher prevalence of vitamin D deficiency in these geographical regions.\(^{(23)}\) Furthermore, the seasonal fluctuation of serum vitamin D level might be responsible for the higher risk of respiratory infections in fall and winter.\(^{(24)}\)

Another link between COVID-19 and vitamin D is the rennin angiotensin system (RAS). It seems that angiotensin converting enzyme 2 (ACE2) is the functional receptor of SARS-CoV-2 to which the virus gets attached and then penetrates into the host cell. During the SARS-CoV-2 infection, tissues, especially lungs, face a loss in ACE2 function followed by an increase in the concentration of angiotensin II which finally leads to increasing alveolar permeability and accelerating lung damage.\(^{(25)}\) Interestingly, vitamin D can increase the expression of ACE2 mRNA which can act as a double-edged sword; on the one hand, it can increase the number of receptors for the virus to enter the cells and on the other hand it can protect the pulmonary tissue from damage by saving the function of ACE2.

A vitamin D concentration was among the parameters with the significant diagnostic accuracy for the early detection of COVID-19 death and requiring invasive mechanical ventilation. Vitamin D seems to have the same or more predictive value than LDH, ESR and CRP for COVID-19 poor outcomes. However, it has lower predictive ability compared to lymphocyte count, creatinine, and CPK. Previously, independent parameters such as underlying comorbidity, older age, higher LDH and lower lymphocyte count were used to develop a scoring model for predicting the progression of COVID-19.\(^{(26)}\)

In conclusion, the present study showed that vitamin D deficiency can be considered as a predictor for poor outcomes and mortality in COVID-19 patients. Therefore, taking vitamin D supplements according to the prophylactic or treatment protocols is recommended as before. In addition, it is suggested that serum vitamin D status be checked in all COVID-19 patients on admission and appropriate action be taken to correct the possible deficiency or insufficiency.

**Declarations**

**Ethics approval and consent to participate**
Ethics approval for the study protocol was granted by The Human Ethics Committee of Alborz University of Medical Sciences (ABZUMS) and Iran University of Medical Sciences (IUMS). All participants signed written informed consent forms.

**Consent for publication**

This is formally to submit the article entitled “The Predictive Power of Serum Vitamin D for Poor Outcomes in COVID-19 Patients” prepared by the Alborz University of Medical Sciences (ABZUMS) and Iran University of Medical Sciences (IUMS) for review and, hopefully, publication in your prestigious journal. The authors would like to advise that all authors listed have contributed to the work. All authors have agreed to submit the manuscript to BMC Endocrine Disorders. No part of the work has been published before. There is no conflict of interest in this paper.

**Availability of data and materials**

The Data are not publicly available because of containing information that could compromise the privacy of research.

**Competing interests**

All authors declared that they have no competing interests.

**Funding**

This study was funded by Iran University of Medical Sciences and Alborz University of Medical Sciences.

**Authors’ contributions**

HD, ZM, HR, MQ, MR, MF, and SG designed the research and collected the samples; MZ, HS, and MZ wrote the paper; TK and HH analyzed data; KM conducted research and had primary responsibility for final content. All authors read and approved the final manuscript.

**Acknowledgements**

The assistance of all researchers and participants who cooperated on this project is gratefully appreciated. This study was funded by Iran University of Medical Sciences and Alborz University of Medical Sciences.
References

1. COVID C, Team R. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-6.

2. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nature Medicine. 2020;26(4):506-10.

3. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020;12(4):988.

4. Hewison M. An update on vitamin D and human immunity. Clinical endocrinology. 2012;76(3):315-25.

5. Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. Journal of Clinical Virology. 2011;50(3):194-200.

6. Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients. 2015;7(6):4240-70.

7. Wei R, Christakos S. Mechanisms underlying the regulation of innate and adaptive immunity by vitamin D. Nutrients. 2015;7(10):8251-60.

8. Alifano M, Alifano P, For gez P, Iannelli A. Renin-angiotensin system at the heart of COVID-19 pandemic. Biochimie. 2020.

9. Mahdavi A, Khalili N, Davarpanah AH, Faghihi T, Mahdavi A, Haseli S, et al. Radiologic management of COVID-19: preliminary experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC). Iranian Journal of Radiology. 2020(In Press).

10. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020:200642.

11. Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020.

12. Alipio M. Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-19). Available at SSRN 3571484. 2020.

13. Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of Vitamin D Deficiency and Treatment with COVID-19 Incidence. medRxiv. 2020.

14. Aranow C. Vitamin D and the immune system. Journal of investigative medicine. 2011;59(6):881-6.

15. Schwalfenberg GK. A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. Molecular nutrition & food research. 2011;55(1):96-108.

16. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
17. Cantorna MT, Snyder L, Lin Y-D, Yang L. Vitamin D and 1, 25 (OH) 2D regulation of T cells. Nutrients. 2015;7(4):3011-21.

18. Ginde AA, Mansbach JM, Camargo CA. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Archives of internal medicine. 2009;169(4):384-90.

19. Laaksi I, Ruohola J-P, Tuohimaa P, Auvinen A, Haataja R, Pihlajamäki H, et al. An association of serum vitamin D concentrations< 40 nmol/L with acute respiratory tract infection in young Finnish men. The American journal of clinical nutrition. 2007;86(3):714-7.

20. Cannell J, Vieth R, Umhau J, Holick M, Grant W, Madronich S, et al. Epidemic influenza and vitamin D. Epidemiology & Infection. 2006;134(6):1129-40.

21. Villamor E. A potential role for vitamin D on HIV infection? Nutrition reviews. 2006;64(5):226-33.

22. Rodriguez M, Daniels B, Gunawardene S, Robbins G. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS research and human retroviruses. 2009;25(1):9-14.

23. Rhodes JM, Subramanian S, Laird E, Anne Kenny R. low population mortality from COVID-19 in countries south of latitude 35 degrees North—supports vitamin D as a factor determining severity. Alimentary pharmacology & therapeutics. 2020.

24. Juzeniene A, Ma L-W, Kwitniewski M, Polev GA, Lagunova Z, Dahlback A, et al. The seasonality of pandemic and non-pandemic influenzas: the roles of solar radiation and vitamin D. International Journal of Infectious Diseases. 2010;14(12):e1099-e105.

25. Rashedi J, Poor BM, Asgharzadeh M. Vitamin D3 Administration to Patients with Confirmed COVID-19. Iranian Journal of Public Health. 2020;49:141-2.

26. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. Clinical Infectious Diseases. 2020.

Figures
Figure 1

Receiver operating characteristic curves of vitamin D deficiency and blood parameters for predicting COVID-19 death (A) and need to ICU care (B). CPK: Creatine phosphokinase, PT: Prothrombin time.